Apollo Endosurgery Inc (NASDAQ:APEN) Major Shareholder Stonepine Capital, L.P. Buys 45,434 Shares

Apollo Endosurgery Inc (NASDAQ:APEN) major shareholder Stonepine Capital, L.P. purchased 45,434 shares of the business’s stock in a transaction dated Wednesday, December 20th. The shares were purchased at an average price of $4.50 per share, with a total value of $204,453.00. Following the acquisition, the insider now directly owns 2,410,141 shares in the company, valued at $10,845,634.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Stonepine Capital, L.P. also recently made the following trade(s):

  • On Saturday, December 29th, Stonepine Capital, L.P. bought 5,163 shares of Apollo Endosurgery stock. The stock was bought at an average price of $5.56 per share, with a total value of $28,706.28.
  • On Wednesday, January 3rd, Stonepine Capital, L.P. bought 22,845 shares of Apollo Endosurgery stock. The stock was bought at an average price of $5.71 per share, with a total value of $130,444.95.
  • On Tuesday, December 26th, Stonepine Capital, L.P. bought 5,287 shares of Apollo Endosurgery stock. The stock was bought at an average price of $5.00 per share, with a total value of $26,435.00.
  • On Friday, December 22nd, Stonepine Capital, L.P. purchased 185,157 shares of Apollo Endosurgery stock. The stock was acquired at an average cost of $4.85 per share, with a total value of $898,011.45.

Shares of Apollo Endosurgery Inc (NASDAQ APEN) opened at $6.31 on Friday. Apollo Endosurgery Inc has a 1 year low of $3.55 and a 1 year high of $17.48. The firm has a market cap of $109.10, a price-to-earnings ratio of -0.17 and a beta of 0.44. The company has a quick ratio of 2.00, a current ratio of 2.54 and a debt-to-equity ratio of 0.58.

Several brokerages have commented on APEN. Roth Capital set a $10.00 price target on shares of Apollo Endosurgery and gave the company a “buy” rating in a research report on Thursday, January 4th. ValuEngine raised shares of Apollo Endosurgery from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd. Zacks Investment Research cut shares of Apollo Endosurgery from a “buy” rating to a “hold” rating in a research report on Wednesday, December 27th. Finally, Northland Securities reaffirmed a “buy” rating and set a $12.00 price objective on shares of Apollo Endosurgery in a research report on Monday, December 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. Apollo Endosurgery has an average rating of “Hold” and an average target price of $9.44.

Institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. acquired a new position in Apollo Endosurgery in the third quarter valued at $119,000. Woodmont Investment Counsel LLC acquired a new position in Apollo Endosurgery in the third quarter valued at $220,000. Russell Investments Group Ltd. acquired a new position in Apollo Endosurgery in the third quarter valued at $1,288,000. King Luther Capital Management Corp acquired a new position in Apollo Endosurgery in the third quarter valued at $2,567,000. Finally, Stonepine Capital Management LLC acquired a new position in Apollo Endosurgery in the third quarter valued at $11,067,000. 23.67% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/14/stonepine-capital-l-p-buys-45434-shares-of-apollo-endosurgery-inc-apen-stock-2.html.

Apollo Endosurgery Company Profile

Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.

Insider Buying and Selling by Quarter for Apollo Endosurgery (NASDAQ:APEN)

Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply